TGF-β family members play a relevant role in tumorigenic processes, including hepatocellular carcinoma (HCC), but a specific implication of the Bone Morphogenetic Protein (BMP) subfamily is still unknown. Although originally isolated from fetal liver, little is known about BMP9, a BMP family member, and its role in liver physiology and pathology. Our results show that BMP9 promotes growth in HCC cells, but not in immortalized human hepatocytes. In the liver cancer cell line HepG2, BMP9 triggers Smad1,5,8 phosphorylation and inhibitor of DNA binding 1 (Id1) expression up- regulation. Importantly, by using chemical inhibitors, ligand trap and gene silencing approaches we demonstrate that HepG2 cells autocrinely produce BMP9 that supports their proliferation and anchorage independent growth. Additionally, our data reveal that in HepG2 cells BMP9 triggers cell cycle progression, and strikingly, completely abolishes the increase in the percentage of apoptotic cells induced by long-term incubation in low serum. Collectively, our data unveil a dual role for BMP9, both promoting a proliferative response and exerting a remarkable anti-apoptotic function in HepG2 cells, which result in a robust BMP9 effect on liver cancer cell growth. Finally, we show that BMP9 expression is increased in 40% of human HCC tissues compared with normal human liver as revealed by immunohistochemistry analysis, suggesting that BMP9 signaling may be relevant during hepatocarcinogenesis in vivo. Our findings provide new clues for a better understanding of BMPs contribution, and in particular BMP9, in HCC pathogenesis that may result in the development of effective and targeted therapeutic interventions.
References
[1]
Massague J (2008) TGFbeta in Cancer. Cell 134: 215–230.
[2]
Urist MR (1965) Bone: formation by autoinduction. Science 150: 893–899.
[3]
Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, et al. (1988) Novel regulators of bone formation: molecular clones and activities. Science 242: 1528–1534.
[4]
Wagner DO, Sieber C, Bhushan R, Borgermann JH, Graf D, et al. (2010) BMPs: from bone to body morphogenetic proteins. Sci Signal 3: mr1.
[5]
Plouhinec JL, Zakin L, De Robertis EM (2011) Systems control of BMP morphogen flow in vertebrate embryos. Curr Opin Genet Dev 21: 696–703.
[6]
Reddi AH, Reddi A (2009) Bone morphogenetic proteins (BMPs): from morphogens to metabologens. Cytokine Growth Factor Rev 20: 341–342.
[7]
Conidi A, Cazzola S, Beets K, Coddens K, Collart C, et al. (2011) Few Smad proteins and many Smad-interacting proteins yield multiple functions and action modes in TGFbeta/BMP signaling in vivo. Cytokine Growth Factor Rev 22: 287–300.
Kim M, Choe S (2011) BMPs and their clinical potentials. BMB Rep 44: 619–634.
[10]
Alarmo EL, Kallioniemi A (2010) Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr Relat Cancer 17: R123–139.
[11]
Singh A, Morris RJ (2010) The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 21: 299–313.
[12]
Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, et al.. (2010) Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 66: 233–246; discussion 246.
[13]
Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, et al. (2011) Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med 208: 2641–2655.
[14]
Feng GS (2012) Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 21: 150–154.
[15]
Herrera B, Sanchez A, Fabregat I (2012) BMPs And Liver: More Questions Than Answers. Curr Pharm Des in press.
[16]
Lu JW, Hsia Y, Yang WY, Lin YI, Li CC, et al. (2012) Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 33: 209–219.
[17]
Maegdefrau U, Amann T, Winklmeier A, Braig S, Schubert T, et al. (2009) Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol 218: 520–529.
[18]
Maegdefrau U, Arndt S, Kivorski G, Hellerbrand C, Bosserhoff AK (2011) Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma. Lab Invest 91: 1615–1623.
[19]
Guo X, Xiong L, Zou L, Zhao J (2012) Upregulation of Bone Morphogenetic Protein 4 is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Pathol Oncol Res 18: 635–640.
[20]
Maegdefrau U, Bosserhoff AK (2012) BMP activated Smad signaling strongly promotes migration and invasion of hepatocellular carcinoma cells. Exp Mol Pathol 92: 74–81.
[21]
Celeste AJ, Song JJ, Cox K, Rosen V, Wozney JM (1994) Bone morphogenetic protein-9, a new member of the TGF-beta superfamily. J Bone Min Res, Supp 1: 136.
[22]
Bidart M, Ricard N, Levet S, Samson M, Mallet C, et al.. (2011) BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci.
[23]
Li Q, Gu X, Weng H, Ghafoory S, Liu Y, et al.. (2013) Bone morphogenetic protein-9 (BMP-9) induces epithelial to mesenchymal transition (EMT) in hepatocellular carcinoma cells. Cancer Sci [Epub ahead of print].
[24]
Zilberberg L, ten Dijke P, Sakai LY, Rifkin DB (2007) A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biol 8: 41.
[25]
de Juan C, Benito M, Alvarez A, Fabregat I (1992) Differential proliferative response of cultured fetal and regenerating hepatocytes to growth factors and hormones. Exp Cell Res 202: 495–500.
[26]
Conner E, Wirth P, Kiss A, Santoni-Rugiu E, Thorgeirsson S (1997) Growth inhibition and induction of apoptosis by HGF in transformed rat liver epithelial cells. Biochem Biophys Res Commun 236: 396–401.
[27]
Herrera B, van Dinther M, Ten Dijke P, Inman GJ (2009) Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res 69: 9254–9262.
[28]
Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, et al. (2010) Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 120: 2842–2857.
[29]
Miller AF, Harvey SA, Thies RS, Olson MS (2000) Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver. J Biol Chem 275: 17937–17945.
[30]
Song JJ, Celeste AJ, Kong FM, Jirtle RL, Rosen V, et al. (1995) Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology 136: 4293–4297.
[31]
Herrera B, Inman GJ (2009) A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol 10: 20.
[32]
Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, et al. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33–41.
[33]
Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, et al. (2008) BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 14: 1363–1369.
[34]
Brown MA, Zhao Q, Baker KA, Naik C, Chen C, et al. (2005) Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 280: 25111–25118.
[35]
Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, et al. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120: 964–972.
[36]
David L, Mallet C, Keramidas M, Lamande N, Gasc JM, et al. (2008) Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 102: 914–922.
[37]
Chen C, Grzegorzewski KJ, Barash S, Zhao Q, Schneider H, et al. (2003) An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol 21: 294–301.
[38]
Kang S, Song J, Kang H, Kim S, Lee Y, et al. (2003) Insulin can block apoptosis by decreasing oxidative stress via phosphatidylinositol 3-kinase- and extracellular signal-regulated protein kinase-dependent signaling pathways in HepG2 cells. Eur J Endocrinol 148: 147–155.
[39]
Wang YD, Yang F, Chen WD, Huang X, Lai L, et al. (2008) Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo. Mol Endocrinol 22: 1622–1632.
[40]
David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953–1961.
[41]
Park JE, Shao D, Upton PD, Desouza P, Adcock IM, et al. (2012) BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One 7: e30075.
[42]
Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, et al. (2010) BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci 123: 1684–1692.
[43]
Cunha S, Pietras K (2011) ALK1 as an emerging target for anti-angiogenic therapy of cancer. Blood.
[44]
Finnson KW, Parker WL, ten Dijke P, Thorikay M, Philip A (2008) ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in human chondrocytes. J Bone Miner Res 23: 896–906.
[45]
Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, et al. (2006) Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology 43: 1032–1041.
[46]
Hsieh SY, He JR, Hsu CY, Chen WJ, Bera R, et al. (2011) Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. Hepatology 53: 504–516.
[47]
Ortiz C, Caja L, Sancho P, Bertran E, Fabregat I (2008) Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion. Biochem Pharmacol 75: 1935–1945.
[48]
Sancho P, Fabregat I (2010) NADPH oxidase NOX1 controls autocrine growth of liver tumor cells through up-regulation of the epidermal growth factor receptor pathway. J Biol Chem 285: 24815–24824.
[49]
Sancho P, Fabregat I (2011) The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF-beta-induced apoptosis of liver tumor cells. Biochem Pharmacol 81: 917–924.
[50]
Caja L, Sancho P, Bertran E, Fabregat I (2011) Dissecting the effect of targeting the epidermal growth factor receptor on TGF-beta-induced-apoptosis in human hepatocellular carcinoma cells. J Hepatol 55: 351–358.
[51]
Horiguchi N, Takayama H, Toyoda M, Otsuka T, Fukusato T, et al. (2002) Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene 21: 1791–1799.
[52]
Ljubimova JY, Petrovic LM, Wilson SE, Geller SA, Demetriou AA (1997) Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45: 79–87.
[53]
Xie Q, Liu KD, Hu MY, Zhou K (2001) SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. World J Gastroenterol 7: 816–820.
[54]
Fransvea E, Angelotti U, Antonaci S, Giannelli G (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47: 1557–1566.
[55]
Sun HC, Tang ZY (2004) Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 130: 307–319.
[56]
Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, et al. (2011) Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res 71: 1362–1373.
